MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verdier-Pinard, P.
Right arrow Articles by Hamel, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verdier-Pinard, P.
Right arrow Articles by Hamel, E.

Vol. 53, Issue 1, 62-76, January 1998

Structure-Activity Analysis of the Interaction of Curacin A, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 Breast Cancer Cells

Pascal Verdier-Pinard, Jing-Yu Lai, Hae-Dong Yoo, Jurong Yu, Brian Marquez, Dale G. Nagle, Mitch Nambu, James D. White, J. R. Falck, William H. Gerwick, Billy W. Day and Ernest Hamel

Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment, and Diagnosis, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 21702 (P.V.-P., E.H.), Departments of Biochemistry and Pharmacology, Southwestern Medical Center, The University of Texas at Dallas, Dallas, Texas 75235 (J.Y.L., J.Y., J.R.F.), College of Pharmacy, Oregon State University, Corvallis, Oregon 97331 (H.-D.Y., B.M., D.G.N., W.H.G.), Department of Chemistry, Oregon State University, Corvallis, Oregon 97331 (M.N., J.D.W.), and Departments of Environmental and Occupational Health and of Pharmaceutical Sciences, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15238 (B.W.D.)

Originally purified as a major lipid component of a strain of the cyanobacterium Lyngbya majuscula isolated in Curaçao, curacin A is a potent inhibitor of cell growth and mitosis, binding rapidly and tightly at the colchicine site of tubulin. Because its molecular structure differs so greatly from that of colchicine and other colchicine site inhibitors, we prepared a series of curacin A analogs to determine the important structural features of the molecule. These modifications include reduction and E-to-Z transitions of the olefinic bonds in the 14-carbon side chain of the molecule; disruption of and configurational changes in the cyclopropyl moiety; disruption, oxidation, and configurational reversal in the thiazoline moiety; configurational reversal and substituent modifications at C13; and demethylation at C10. Inhibitory effects on tubulin assembly, the binding of colchicine to tubulin, and the growth of MCF-7 human breast carcinoma cells were examined. The most important portions of curacin A required for its interaction with tubulin seem to be the thiazoline ring and the side chain at least through C4, the portion of the side chain including the C9-10 olefinic bond, and the C10 methyl group. Only two modifications totally eliminated the tubulin-drug interaction. The inactive compounds were a segment containing most of the side chain, including its two substituents, and analogs in which the methyl group at the C13 oxygen atom was replaced by a benzoate residue. Antiproliferative activity comparable with that observed with curacin A was only reproduced in compounds that were potent inhibitors of the binding of colchicine to tubulin. Molecular modeling and quantitative structure-activity relationship studies demonstrated that most active analogs overlapped extensively with curacin A but failed to provide an explanation for the apparent structural analogy between curacin A and colchicine.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
T. L. Simmons, R. C. Coates, B. R. Clark, N. Engene, D. Gonzalez, E. Esquenazi, P. C. Dorrestein, and W. H. Gerwick
Chemical Ecology Special Feature: Biosynthetic origin of natural products isolated from marine microorganism-invertebrate assemblages
PNAS, March 25, 2008; 105(12): 4587 - 4594.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. S. Raccor, A. Vogt, R. P. Sikorski, C. Madiraju, R. Balachandran, K. Montgomery, Y. Shin, Y. Fukui, W.-H. Jung, D. P. Curran, et al.
Cell-Based and Biochemical Structure-Activity Analyses of Analogs of the Microtubule Stabilizer Dictyostatin
Mol. Pharmacol., March 1, 2008; 73(3): 718 - 726.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
L. Gu, T. W. Geders, B. Wang, W. H. Gerwick, K. Hakansson, J. L. Smith, and D. H. Sherman
GNAT-Like Strategy for Polyketide Chain Initiation
Science, November 9, 2007; 318(5852): 970 - 974.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Sharifi, E. Hamel, M. A. Lill, P. Risbood, C. T. Kane Jr., M. T. Hossain, A. Jones, J. T. Dalton, and W. L. Farrar
A bifunctional colchicinoid that binds to the androgen receptor
Mol. Cancer Ther., August 1, 2007; 6(8): 2328 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. L. Mooberry, K. N. Weiderhold, S. Dakshanamurthy, E. Hamel, E. J. Banner, A. Kharlamova, J. Hempel, J. T. Gupton, and M. L. Brown
Identification and Characterization of a New Tubulin-Binding Tetrasubstituted Brominated Pyrrole
Mol. Pharmacol., July 1, 2007; 72(1): 132 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno, G. Hallur, A. Chan, X. Zhang, G. Cusatis, F. Chan, P. Shah, R. Chen, E. Hamel, E. Garrett-Mayer, et al.
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer
Mol. Cancer Ther., May 1, 2007; 6(5): 1509 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. J. Bonham, A. Galkin, B. Montgomery, W. L. Stahl, D. Agus, and P. S. Nelson
Effects of the Herbal Extract PC-SPES on Microtubule Dynamics and Paclitaxel-Mediated Prostate Tumor Growth Inhibition
J Natl Cancer Inst, November 6, 2002; 94(21): 1641 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. A. Ojo-Amaize, E. J. Nchekwube, H. B. Cottam, R. Bai, P. Verdier-Pinard, V. N. Kakkanaiah, J. A. Varner, L. Leoni, J. I. Okogun, A. A. Adesomoju, et al.
Hypoestoxide, a Natural Nonmutagenic Diterpenoid with Antiangiogenic and Antitumor Activity: Possible Mechanisms of Action
Cancer Res., July 15, 2002; 62(14): 4007 - 4014.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. S. Lazo, K. Tamura, A. Vogt, J.-K. Jung, S. Rodriguez, R. Balachandran, B. W. Day, and P. Wipf
Antimitotic Actions of a Novel Analog of the Fungal Metabolite Palmarumycin CP1
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 364 - 371.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
L. M. Leoni, E. Hamel, D. Genini, H. Shih, C. J. Carrera, H. B. Cottam, and D. A. Carson
Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells
J Natl Cancer Inst, February 2, 2000; 92(3): 217 - 224.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics